Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Key facts
- Where
- Hellerup, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07506369, who can take part
Where in Denmark
- Center for Clinical Metabolic Research, Gentofte HospitalHellerup, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Gentofte, Copenhagen
- Trial code
- NCT07506369
- Record updated
- 1 April 2026
- Original description
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones.Read full original descriptionShow less
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones.
The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours:
A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.
Inclusion: Male; Age between 18 and 65 years at the time of inclusion; Body mass index 18-27 kg/m2; Fat percentage < 20%; Informed oral and written consent.
Exclusion: Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery); Previous pancreatic disease and/or neoplasia; Initiation of special diets, lifestyle changes and/or weight loss >5% of total body weight within three months prior to or during study period; History of hepatobiliary and/or gastrointestinal disorder(s); Kidney disease; Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation; Anaemia (haemoglobin below normal range); Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment; Regular tobacco smoking and/or use of other nicotine products.